Pharmaceutical manufacturers of Gabapentin

Lonza stands as a prominent supplier in the Pharma&Biotech and Specialty Ingredient markets on a global scale. Our utilization of science and technology allows us to develop a diverse range of products that promote healthier lives for both humans and animals, while also improving overall well-being. The selection includes active pharmaceutical ingredients, stem-cell therapies, drinking water sanitizers, industrial preservatives, microbial control solutions, vitamin B compounds, organic personal care ingredients, and agricultural services and products.

We are one of world’s leading producers of key Active Pharmaceutical Ingredients (APIs) and generic formulations with presence in 140+ countries and backed by 30 years of experience in the pharma sector. We endeavour to serve patients by moulding science and technology into therapies to improve health outcomes and people’s lives.

OLON Group is a prominent worldwide firm specializing in the creation and manufacture of active pharmaceutical ingredients for CDMO and Generics. It serves as a dependable and preferred partner for the pharmaceutical, biotech, and specialty ingredients sectors. With a 2021 turnover of 580 million dollars, OLON provides 300 APIs for the Generic market. The company benefits from a workforce of 2,300 employees, including a highly skilled R&D team of over 300 individuals. This enables OLON to offer comprehensive integrated packages and services to facilitate the full development of APIs, leveraging extensive expertise in both Chemical and Biological processes, all within a full cGMP and regulatory framework. OLON holds approximately 160 active US DMFs and 79 granted CoS. OLON's headquarters is located in Rodano, near Milan, Italy, and it operates 11 manufacturing facilities - 8 in Italy, 1 in Spain, 1 in the USA, and 1 in India. These facilities are designed in accordance with the most stringent international standards. Additionally, OLON has 3 branch offices in Hamburg (Germany), Florham Park, NJ (USA), and Shanghai (China).

Sicor, situated in the northern region of Italy, is a component of the Teva API business and offers a worldwide platform for the production and promotion of APIs for injectable, inhalation, topical, and nasal products. These specialized facilities possess a significant level of skill, manufacturing approximately 60 active pharmaceutical ingredients.

In just over a decade, Laurus has positioned itself as one of the largest and most innovative API producers globally. Expanding upon its established expertise in chemistry, Laurus has recently adopted full vertical integration, including a strong finished dosage capacity, dedicated capacity for backward integration, and also Synthesis R&D operations in India and the USA.

Wockhardt UK (WUK) operates as a diverse pharmaceutical company, serving as a significant provider of healthcare products to the NHS through hospitals, multiple retail pharmacy chains, and wholesalers. It is currently experiencing an exciting period with thriving export and contract manufacturing divisions. Leveraging the global strength, research base, and impressive product pipeline of its parent company, Wockhardt UK is well-positioned for future growth.

Granules India Limited is a rapidly expanding pharmaceutical company with top-notch amenities for APIs, PFIs and Finished Dosages, catering to clients in more than 60 nations. We are dedicated to upholding high standards in production, excellence and client relations. Our main office is situated in Hyderabad, and we also have branches in the United States, United Kingdom, Colombia and China, as well as production facilities in India and China.

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

Solara is an API manufacturer focused on research and customer satisfaction, operating in over 75 countries. They specialize in producing APIs for niche therapeutic categories, including complex products like polymer-based APIs and injectable APIs. The company has a team of experienced scientists supported by 6 manufacturing facilities and 2 R&D centers. Additionally, Solara offers Contract Research and Manufacturing Services (CRAMS) from discovery to late phase commercial manufacturing. Solara Active Pharma Sciences, with roots in Strides Shasun Ltd. and Sequent Scientific Ltd., is committed to providing value-based products while prioritizing customer needs. The company has 140+ scientists working at 2 R&D centers and 4 API manufacturing facilities, all with global approvals and 2 dedicated R&D facilities.

Fisvi is a distinguished Italian company with a proud heritage in the manufacturing and innovation sectors. Specializing in advanced materials and cutting-edge solutions, Fisvi offers a wide range of products tailored to meet the demands of various industries, including construction, automotive, and industrial applications. Their product lineup includes high-quality insulation materials, adhesives, sealants, and other specialized components designed to enhance performance and durability.

Hua Hai Pharmaceutical Co., Ltd. is a leading Chinese pharmaceutical company offering a comprehensive range of products and services. They specialize in the production of active pharmaceutical ingredients (APIs) and finished dosage forms, including tablets, capsules, injectables, and oral solutions. Their product portfolio addresses various therapeutic areas such as cardiovascular health, anti-infectives, and central nervous system disorders. The company is committed to innovation through significant investment in research and development, aiming to discover new treatments and enhance existing ones. With state-of-the-art manufacturing facilities adhering to international quality standards, Hua Hai Pharmaceutical is dedicated to delivering high-quality and effective pharmaceutical solutions to global markets.

Glenmark Life Sciences Limited is a prominent producer and developer of specialized, high-value, non-generic, active pharmaceutical ingredients (APIs) within chronic therapeutic fields such as heart disease, disorders of the central nervous system, pain management, and diabetes. The corporation is progressively offering CDMO services to various multinational and specialized pharmaceutical firms. It maintains a varied collection of over 137 compounds and delivers its merchandise to clients in India, Europe, North America, Latin America, Japan, and other parts of the globe (ROW).

Erregierre, with its two manufacturing facilities, one situated in San Paolo D'Argon (Bergamo) and the other in Sovere (Bergamo), is a privately owned independent company from Italy established in 1974. It is a leading producer of pharmaceutical active components created through synthesis and distributed globally. Erregierre has undergone inspection by the FDA and is deeply dedicated to manufacturing in strict compliance with cGMPs and the highest global quality standards.

Teva's roots are deeply rooted in the land of Israel since 1901 in Jerusalem. That's when the first chapter was written in the long and unique history of the company, which slowly transformed from a small drug trading house to the largest generic company in the world, improving the health of millions of patients in Israel and around the world every day.

Maithri Drugs stands as one of the rapidly emerging pharmaceutical firms in India. Maithri's primary emphasis is on active pharmaceutical ingredients (APIs). The corporation is widely acknowledged for its exceptional research & development and ambitious expansion approaches. Our 125+Global DMFs, including 50 in the United States and 22 in the EU within a brief duration, bear witness to our R&D superiority. Maithri's production site is situated in Hyderabad. This site is scrutinized and endorsed by the US FDA. Furthermore, our facility is accredited in accordance with the criteria of DCGI, WHO GMP, and ISO 9001.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

Established in 1993, SUANFARMA is a business-to-business partner in the field of life sciences specializing in the formulation, manufacture, and marketing of components for the pharmaceutical, veterinary, and nutraceutical sectors. In SUANFARMA, we provide our CDMO capabilities for fermentation and chemical synthesis projects, delivering a comprehensive service with a proven track record, facilitating success in the formulation, expansion, production, and marketing of an API, whether it is innovative or generic

Suven Pharmaceuticals Limited, an organization established in November 2018, has transformed into a Wholly Owned Subsidiary of Suven Life Sciences Limited, effective from February 2019. Suven Life Sciences Limited, following the Board meeting on February 5, 2019, declared the demerger of Suven Life Sciences Limited into two parts: Suven Life Sciences Limited, the demerged entity, will persist in pioneering research dedicated to Central Nervous System (CNS) disorders to address significant unmet medical needs worldwide. Suven Pharmaceuticals Limited, the resulting entity, will carry on the CRAMS business operations.

CBC offers outsourcing services for a diverse range of active pharmaceutical ingredients (API) and intermediates, and is also involved in the trade of agrochemical compounds. Additionally, CBC is expanding its operations to include manufacturing, utilizing cutting-edge technology and original research in collaboration with partner companies in each sector. With a focus on health, safety, and convenience, the company is actively engaged in Fine Chemicals, Pharmaceuticals, and Agrochemicals. Its services encompass the supply of the aforementioned products from various sources, support for contract manufacturing of advanced intermediates and bulk actives, as well as representation of various named chemicals and pharmaceutical manufacturers.

SMS Lifesciences is a prominent participant in APIs/Intermediates production with a robust research and manufacturing team supported by cutting-edge facilities. Originating as a single-facility, single-product manufacturer in 1990, it has expanded into a multi-location group with products spanning various therapeutic segments. In 1997-98, SMS Group was accorded the export house status. Currently, SMS Lifesciences is a publicly listed company with a continuously expanding international and domestic customer base.